Longeveron Inc. (LGVN)
LGVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.15
-12.24% on the day
Market cap
$6.9M
Nano cap
Revenue · 2025
$1.2M
-49.9% on 2024
Net income · 2025
-$22.7M
-1893.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | LGVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001721484 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2M |
| Net income | -$22.7M |
| Operating income | -$23.3M |
| Net margin | -1893.6% |
| Operating margin | -1942.2% |
| Revenue growth | -49.9% |
| Cash | $4.7M |
| Total assets | $10.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-04-17 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-14 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-05-20 |
Source: SEC EDGAR submissions feed, 529 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SKYE | Skye Bioscience Inc. | $1.53 | -3.17% | $6.8M |
| ACXP | Acurx Pharmaceuticals Inc. | $1.20 | -6.25% | $6.7M |
| NRSN | NeuroSense Therapeutics Ltd. | $3.49 | +0.29% | $6.6M |
| APUS | Apimeds Pharmaceuticals US Inc. | $4.62 | -11.15% | $7.1M |
| ALZN | Alzamend Neuro Inc. | $1.35 | +3.05% | $6.5M |
| FBLG | FibroBiologics Inc. | $0.9599 | -4.01% | $6.5M |
| SNGX | Soligenix Inc. | $0.3348 | -4.80% | $7.3M |
| INM | InMed Pharmaceuticals Inc. Common Shares | $1.33 | -2.21% | $7.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier